SCHEMBL2803207

SCHEMBL2803207

CCOC(=O)c1cnn2c(Cl)c(C(=O)N3CCC4(CC3)COc3cccc(F)c34)cnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.41
RAB9A P51151 8/20 0.41
KDM4E B2RXH2 7/20 0.41
ALDH1A1 P00352 8/20 0.38
HPGD P15428 6/20 0.38
SMN1; SMN2 Q16637 6/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.37
HSD17B10 Q99714 4/20 0.37
BRAF P15056 4/20 0.37
MAPT P10636 2/20 0.36
NFKB1 P19838 2/20 0.36
NFKB2 Q00653 2/20 0.36
RELA Q04206 2/20 0.36
TP53 P04637 1/20 0.35
STAT1 P42224 1/20 0.35
GAA P10253 1/20 0.35
AVPR1A P37288 1/20 0.35
MEN1 O00255 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2798540 0.91 NPC1 (0.42) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2800592 0.88 KDM4E (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2801299 0.88 AVPR1A (0.47) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2801509 0.85 KDM4E (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2801500 0.84 ALDH1A1 (0.37) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2799589 0.80 KDM4E (0.41) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2802452 0.79 AVPR1A (0.44) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2801589 0.79 KDM4E (0.47) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2800441 0.78 KDM4E (0.45) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL2801942 0.78 KDM4E (0.47) NPC1RAB9AKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 NPC1 1787/4885RAB9A 3259/4885KDM4E 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.